Sign In
15 May 2015 11:04
Press release
Synairgen plc
('Synairgen' or the 'Company')
Notice of Annual General Meeting
Southampton, UK - 15 May 2015: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that notice of its 2015 Annual General Meeting ('AGM') has been posted to shareholders and is available on the Company's website, www.synairgen.com. The AGM will be held at 11 a.m. on Monday 22 June 2015 at the offices of Fasken Martineau LLP, 17 Hanover Square, London W1S 1HU.
Ends
For further information, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800
FinnCap
Geoff Nash / James Thompson (Corporate Finance)
Stephen Norcross / Simon Johnson (Corporate Broking)
Tel: + 44 (0) 20 7220 0500
Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott / Jessica Hodgson / Laura Thornton
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5701
About Synairgen
Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging scientific and clinical trial facilities at the University of Southampton and Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development. Core to Synairgen's business strategy is the realisation of value via licensing transactions - validated in June 2014 by the SNG001 agreement formed with AstraZeneca. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com.
Follow the stocks
